KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank58
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-3.41
↑ 17% vs avg
Percentile
P58
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
-4.12
Historical baseline
PeriodValueYoY Change
2025-3.41-16.6%
2024-2.93-38.5%
2023-2.11+41.0%
2022-3.58+52.5%
2021-7.53-67.9%
2020-4.48+58.1%
2019-10.70-308.4%
2018-2.62-48.0%
2017-1.77+15.5%
2016-2.09-